companies / verdiviabio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-04-30 json
| total_raised | 411,000,000411.0M | ○ |
|---|---|---|
| founded | null | |
| hq | London | |
| industry | unknown | |
| stage | series-a |
Verdiva Bio is a UK clinical-stage biotech advancing oral GLP-1 and incretin-based therapies for obesity and cardiometabolic disease. Patients with obesity are the eventual target population. The lead program VRB-101 is in Phase 2 trials as a once-weekly oral peptide.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-01-01 | series-a | 411,000,000411.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Series A, $411.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |